EGF Theramed Health (TSE:TMED)

:TMED

TMED

EGF Theramed Health

RESEARCH TOOLSreports

Want to see TSE:TMED full AI Analyst Report?

EGF Theramed Health (TMED) Price & Analysis

6 Followers

TMED Stock Chart & Stats

C$0.07

C$0.00(0.00%)

At close: Dec 30 4:00 PM EST

C$0.07

C$0.00(0.00%)

Day’s Range― - ―

52-Week RangeC$0.06 - C$0.13

Previous CloseN/A

Volume0.00

Average Volume (3M)1.23K

Market Cap

C$929.33K

Enterprise ValueC$3.04M

Total Cash (Recent Filing)C$10.47K

Total Debt (Recent Filing)C$1.63M

Price to Earnings (P/E)―

Beta0.46

Next Earnings

Jun 02, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.27

Shares Outstanding11,616,665

10 Day Avg. Volume1,800

30 Day Avg. Volume1,233

Financial Highlights & Ratios

PEG Ratio>-0.01

Price to Book (P/B)-0.26

Price to Sales (P/S)0.00

P/FCF Ratio38.98

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Improving Cash Generation In 2025The shift to slightly positive operating and free cash flow in 2025 demonstrates an initial ability to generate cash internally. While small, this improvement is a durable indicator management can begin to fund operations without sole reliance on external financing, aiding short-to-medium term stability.

Trend Of Reduced Net LossesA sustained reduction in annual net losses from the 2020 trough through 2021–2024 indicates management has been cutting costs or right-sizing the business. This trend, if continued, supports a durable path toward breakeven by improving operational discipline and lowering the structural loss base.

Very Small Asset Base (asset-light Profile)A minimal asset base and zero reported employees imply an asset-light operating footprint. Structurally, asset-light models can scale with lower incremental capex and enable faster pivots in healthcare information services, preserving capital for product development or strategic partnerships if traction appears.

Bears Say

No Reported RevenueZero reported revenue across all years is a critical structural weakness: it signals absent product-market traction and no recurring cash inflows. Without revenue, the company cannot sustain margins or fund growth internally, making long-term viability dependent on external capital or a material business pivot.

Negative Equity And Solvency PressureNegative shareholders' equity and a meaningful debt load relative to a tiny asset base create persistent solvency and recapitalization risk. Structurally this limits financial flexibility, raises creditor/dilution risk, and constrains ability to invest in product or sales capacity over the medium term.

Persistent Operating Losses And Negative MarginsOngoing negative operating results and EBITDA losses indicate the business lacks sustainable margins. Persistent losses consume capital, hinder reinvestment, and increase dependency on external funding; the 2025 deterioration underscores volatility and structural challenges to achieving profitability.

EGF Theramed Health News

EGF Theramed refreshes board and finance leadership

EGF Theramed Health ( ($TSE:TMED) ) has shared an announcement. EGF Theramed Health Corp. has appointed Lin Ye...

3M ago

TMED FAQ

What was EGF Theramed Health’s price range in the past 12 months?

EGF Theramed Health lowest stock price was C$0.06 and its highest was C$0.13 in the past 12 months.

What is EGF Theramed Health’s market cap?

EGF Theramed Health’s market cap is C$929.33K.

When is EGF Theramed Health’s upcoming earnings report date?

EGF Theramed Health’s upcoming earnings report date is Jun 02, 2026 which is in 12 days.

How were EGF Theramed Health’s earnings last quarter?

EGF Theramed Health released its earnings results on Feb 24, 2026. The company reported -C$0.006 earnings per share for the quarter, missing the consensus estimate of N/A by -C$0.006.

Is EGF Theramed Health overvalued?

According to Wall Street analysts EGF Theramed Health’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does EGF Theramed Health pay dividends?

EGF Theramed Health does not currently pay dividends.

What is EGF Theramed Health’s EPS estimate?

EGF Theramed Health’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does EGF Theramed Health have?

EGF Theramed Health has 11,616,665 shares outstanding.

What happened to EGF Theramed Health’s price movement after its last earnings report?

EGF Theramed Health reported an EPS of -C$0.006 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of EGF Theramed Health?

Currently, no hedge funds are holding shares in TSE:TMED

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

EGF Theramed Health

EGF Theramed Health Corp. provides psychedelic drugs for the treatment of mental health. It offers psychedelics for the treatment of conditions, such as treatment-resistant depression, anxiety, PTSD, and depression. The company was incorporated in 2011 and is headquartered in Vancouver, Canada.